Search PubMed⌕ Search

Biomedical subjects

L Ellman

Publications and source records attributed to L Ellman.

66 records · Page 4Linked to original sources
PubMed1970

Histocompatibility type and immune responsiveness in random bred Hartley strain guinea pigs.

Outbred Hartley strain guinea pigs capable of responding immunologically to 2,4-dinitrophenylated poly-L-lysine were shown to display a histocompatibility specificity in common with inbred strain 2 guinea pigs. This histocompatibility specificity was not detected in guinea pigs unable to respond immunologically to DNP-PLL. The result suggests that the poly-L-lysine specific immune response gene is very closely linked or even identical with a gene determining a major histocompatibility antigen in guinea pigs.

Animals↗
PubMed1970

Genetically controlled total deficiency of the fourth component of complement in the guinea pig.

Guinea pigs with a total deficiency of the fourth component of complement (C4) have been discovered. There was no evidence for the presence of a C4 inhibitor in the serum of these animals. Mating studies indicate that C4 deficiency is transmitted as a simple autosomal recessive trait. A colony of these animals is being established at the National Institutes of Health. They will provide an opportunity to more precisely define the role of complement in immune phenomena and the defense against disease.

Animals↗
PubMed1970

Linkage between the poly-L-lysine gene and the locus controlling the major histocompatibility antigens in strain 2 guinea pigs.

The data presented demonstrate linkage between the major histocompatibility locus of inbred strain 2 guinea pigs and a "specific immune response gene," the PLL gene, which controls responsiveness to poly-L-lysine and hapten conjugates of this polypeptide in these animals. This finding extends to another species and to a different immune system the linkage observed in mice between the H(2) locus and specific immune response genes at the Ir-1 locus. The general significance of the linkage of specific immune response genes to histocompatibility loci is discussed.

Animals↗
PubMedDate not supplied

The lupus anticoagulant.

The clinical and laboratory experience with the lupus anticoagulant was reviewed in 37 patients. The anti-coagulant is thought to act by blocking the activation of prothrombin by the prothrombin activator comlex of factors Xa, V, and phospholipid. Although the anticoagulant has been principally associated with diseases of immune origin, 14 of the present patients had disorders not thought to be immune in nature. Eighteen patients underwent twenty-one operative procedures with only a single episode of excessive bleeding. In the author's experience, the lupus anticoagulant is a rare cause of bleeding.

Blood Coagulation↗
PubMedDate not supplied

The clinical correlates of IgM M-components: an analysis of thirty-four patients.

Thirty-four patients with an IgM M-component were evaluated for clinical presentation and course, laboratory data, and histologic findings. An attempt was made to ignore the presence of the IgM M-component and to assign each patient to one of the following categories: Waldenstrom's macroglobulinemia, IgM myeloma, Hodgkin's disease, lymphoma, chronic lymphocytic leukemia, chronic lymphosarcoma cell leukemia, and IgM M-components not associated with an identifiable lymphoproliferative disorder ("benign" M-component). Although transitional forms occasionally occurred, most patients could be readily categorized. The patients with lymphoma, Hodgkin's disease, chronic lymphocytic leukemia, and chronic lymphosarcoma cell leukemia did not appear to behave differently from patients with these disorders who did not have serum IgM M-component. Both for descriptive convenience and for clinical management, continued attempts should be made to separate patients with IgM M-components according to their underlying conditions.

Adult↗
PubMedDate not supplied

Plasma heparin neutralizing activity in patients with valvular stenosis and prosthetic heart valves.

Patients with mitral and aortic valvular stenosis had plasma heparin neutralizing activity (HNA) which were comparable to the control group. In contrast, plasma HNA was elevated in patients with prosthetic valves, particularly in the group with prosthetic aortic valves. Neither the type nor the size of the valve appeared to influence the HNA level. No correlation was evident between plasma HNA levels and a history of systemic arterial embolism. It remains to be determined whether elevated plasma HNA levels result from platelet aggregation on the valve surface, or from platelet lysis due to turbulence around the prosthetic valve.

Aortic Valve↗